Purpose CHEK2*1100delC heterozygosity has been associated with increased risk of breast, prostate, and colorectal cancer in case-control studies. We tested the hypothesis that CHEK2*1100delC heterozygosity in the general population increases the risk of cancer in general, and breast, prostate, and colorectal cancer in particular.
INTRODUCTION
In most countries, women with breast cancer and a familial predisposition to this disease are offered screening for mutations in all of the BRCA1 and BRCA2 genes. However, in fewer than a quarter of the women screened, a causative mutation is found in either of these two genes. Besides mutations in the BRCA1 and BRCA2 genes, the common CHEK2*1100delC mutation is the most likely candidate to explain genetic risk of breast cancer. [1] [2] [3] [4] [5] [6] [7] [8] [9] CHEK2 (OMIM 604373) is a key checkpoint kinase that acts as a tumor suppressor in response to DNA double-strand breakage. 1 DNA damage results in activation of cell-cycle checkpoints that block cell proliferation and initiate DNA repair. 1 Impaired function of such checkpoints can lead to genomic instability and susceptibility to cancer. Through its ability to phosphorylate p53, Cdc25c, and BRCA1, CHEK2 leads to cell cycle arrest or apoptosis. The first evidence suggesting the implication of CHEK2 in cancer development was the germline mutation CHEK2*1100delC found in several Li-Fraumeni and Li-Fraumeni-like families. 2, 3 The CHEK2*1100delC variant is caused by a deletion of a single cytosine at position 1100, resulting in the introduction of a stop codon after aminoacid 380, 2 and in complete loss of CHEK2 kinase activity. Apart from the association with the Li-Fraumeni syndromes, CHEK2*1100delC heterozygosity has also been associated with breast, [4] [5] [6] [7] [8] [9] prostate, 10, 11 and colorectal cancer 7, 12 ; CHEK2*1100delC heterozygosity are found in 1.1% to 1.4% of white people in Northern Europe. 6, 9 These studies [4] [5] [6] [7] [8] [9] [10] [11] [12] were all case-control studies and the effect of CHEK2*1100delC heterozygosity in the general population has never previously been examined.
We tested the hypothesis that CHEK2*1100delC heterozygosity in the general population increases the risk of cancer in general, and breast, prostate, and colorectal cancer in particular. For this purpose, we genotyped 9,231 individuals from the Danish general population who were observed for 34 years, and the risk of 24 other cancer subtypes were examined in exploratory analyses. Furthermore, we also genotyped 1,101 consecutively collected female breast cancer patients from a large surgical department and compared them with 4,665 female controls from the general population.
PATIENTS AND METHODS

Study Populations
For the prospective study, we examined 9,231 individuals (randomly selected after age and sex stratification) from the Danish general population who participated in the 1991 to 1994 Copenhagen City Heart Study [13] [14] [15] 20 Controls were 4,665 women from the general population (The Copenhagen City Heart Study) within the same age range as the patients, who had no history of breast cancer before the end of 2002.
Ethics
All participants gave written informed consent. Herlev University Hospital and Danish ethical committees approved the studies (No. 100.2039/91, KA02152).
Genotyping
Leukocyte DNA was used to amplify a 251 base pair (bp) long fragment flanking the CHEK2-position 1100 bp in exon 10 by polymerase chain reaction (PCR) using two primers (sense, carboxyfluorescein-labeled, 5Ј-TAA TTT AAG CAA AAT TAA ATG TCC-3Ј; antisense 5Ј-GTT CCA CAT AAG GTT CTC AT-3Ј). Due to CHEK2-pseudogenes on chromosomes 15 and 16, we paid careful attention to avoid pseudogene sequences in the 3Ј ends of the primers. Fragment length of the PCR product was determined by the Megabase 500 system (GE Healthcare, Hilleroed, Denmark), exploiting the length difference of 1 bp between the normal and variant allele. All heterozygotes were sequenced to confirm the genotype, on an independent PCR reaction. All participants were genotyped using identical procedures run in the same lab. Each run included positive and negative controls.
Statistical Analyses
We used the statistical software STATA (STATA/SE for Windows, version 8.2; Stata Corp, College Station, TX). Two-sided P Ͻ .05 was significant. We used the Mann-Whitney U test or Pearson's 2 test. In the prospective study, we used Cox regression with delayed entry and used age as the underlying time variable; we thus automatically adjusted for age. Multifactorially adjusted models also included time- ), smoking (current smoker v nonsmoker), alcohol consumption (0 g/wk v Ͼ 0 g/wk), and smoking history (ever smoker v never smoker). Multifactorial adjustment for brain/nerve tissue cancers, leukemia, and kidney cancer included age and sex, and adjustments for prostate cancer only included age. The proportional hazards assumption based on Schoenfeld residuals was appropriate for all comparisons. A two-factor interaction term tested for interaction in the Cox regression.
The case-control study was matched with a 1-year age strata to perform conditional logistic regression. This resulted in 64 strata with a mean of 4.2 controls per patient. A two-factor interaction term tested for interaction in the logistic regression model.
Population attributable risk was estimated as [f(HRϪ1)]/[1ϩf(HRϪ1)]
, where f is the frequency of CHEK2*1100delC in the population and HR is the hazard ratio for breast cancer.
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Absolute risks for breast cancer by CHEK2*1100delC heterozygosity were estimated by using the regression coefficients from a Poisson regression model with the following covariates: body mass index in two groups (Ͻ 25 kg/m 2 v Ն 25 kg/m 2 ), age in three groups (Ͻ 40 years, 40 to 60 years, and Ͼ 60 years), and use of hormone replacement therapy (no v yes) at the date of blood sampling. Absolute risks are presented as estimated incidence rates (events/10 years) in percentages.
Role of the Funding Organizations
The funding organizations had no role in the design or conduct of the study, or in the collection, management, analysis, and interpretation of the data, or in the preparation, review, or approval of the manuscript.
RESULTS
Prospective Study
Of the general population, 0.5% were CHEK2*1100delC heterozygotes and 99.5% were noncarriers. No homozygotes were identified. This distribution was in Hardy-Weinberg equilibrium ( 2 test, P ϭ .81). Characteristics of the participants are listed in Table 1 . There were no significant differences between heterozygotes and noncarriers for any of these established risk factors for cancer in either study (data not shown).
Hypotheses Testing
During the 34 years of follow-up, we detected 1,914 participants with a first incidence of cancer (Table 1) . Cancer incidences for noncarriers and heterozygotes, for both sexes combined, were 70 and 114 per 10,000 person-years, respectively. Equivalent values were 68 and 66 in women, respectively, and 71 and 180 in men, respectively. The age-adjusted hazard ratios for heterozygotes versus noncarriers were 1.4 (95% CI, 0.9 to 2.4) for men and women combined, 1.0 (95% CI, 0.4 to 2.3) for women alone, and 1.8 (95% CI, 1.0 to 3.4) for men alone. After multifactorial adjustment for the covariates that have been listed in Table 1 , the equivalent hazard ratios were 1.2 (95% CI, 0.7 to 2.1) for men and women combined, 1.1 (95% CI, 0.4 to 2.6) for women alone, and 1.5 (95% CI, 0.7 to 2.9) for men alone. Genotype and sex did not interact with the risk of all cancer (P ϭ .20).
Among women, incidences of breast cancer in noncarriers and CHEK2*1100delC heterozygotes were 17 and 39 per 10,000 personyears, respectively ( Table 2 ). The age-adjusted hazard ratio of breast cancer for heterozygotes versus noncarriers was 2.5 (95% CI, 0.8 to 7.7), which increased to 3.2 (95% CI, 1.0 to 9.9) after multifactorial adjustment. Among men, incidences of prostate cancer in noncarriers versus heterozygotes were 9 and 31 per 10,000 person-years, respectively. The age-adjusted hazard ratio of prostate cancer for heterozygotes versus noncarriers was 2.3 (95% CI, 0.6 to 9.5). In women and men combined, incidences of colorectal cancer in noncarriers versus heterozygotes were 7 and 14 per 10,000 person-years, respectively. Age-adjusted and multifactorially adjusted hazard ratios of colorectal cancer in heterozygotes versus noncarriers were 1.7 (95% CI, 0.4 to 6.7) and 1.6 (95% CI, 0.4 to 6.5).
Exploratory Analyses
Incidences of brain/nerve tissue cancer in noncarriers versus heterozygotes were 1 and 14 per 10,000 person-years, respectively ( Table 2 ). Age-adjusted and multifactorially adjusted hazard ratios for brain or nerve tissue cancers in heterozygotes versus noncarriers were 10.1 (95% CI, 2.4 to 41.9) and 9.9 (95% CI, 2.4 to 41.2). Incidences of leukemia in noncarriers versus heterozygotes were 2 and 14 per 10,000 person-years, respectively. Age-adjusted and multifactorially adjusted hazard ratios for leukemia in heterozygotes versus noncarriers were 6.7 (95% CI, 1.6 to 27.7) and 6.3 (95% CI, 1.5 to 26.1). Incidences of kidney cancer in noncarriers versus heterozygotes were 1 and 14 per 10,000 person-years, respectively. Age-adjusted and multifactorially adjusted hazard ratios of kidney cancer in heterozygotes versus noncarriers were 10.8 (95% CI, 2.6 to 45.7) and 9.8 (95% CI, 2.3 to 41.2). CHEK2*1100delC heterozygosity was not associated with increased risk of any of the remaining 21 site-specific cancers.
Case-Control Study
The overall odds ratio for invasive breast cancer in heterozygotes versus noncarriers was 2.6 (95% CI, 1.3 to 5.4; Fig 1) . After stratification, odds ratios were 2.8 (95% CI, 1.0 to 7.9) in women older than 60 years, 3.5 (95% CI, 1.4 to 9.0) in women with body mass indexes of 25 kg/m 2 or higher, 3.0 (95% CI, 1.4 to 6.5) in women with any weekly alcohol intake, 3.2 (95% CI, 1.4 to 7.1) in postmenopausal women, and 6.7 (95% CI, 1.4 to 32.7) in women currently using hormone replacement therapy. In the other contexts examined, odds ratios were not significant. Genotype did not, however, interact significantly with any of the contexts examined (Fig 1) .
After stratification for histologic subtypes of breast cancer, the odds ratio was 2.3 (95% CI, 1.0 to 5.5) for ductal tumor; for other histologic subtypes, the odds ratios were nominally higher, but not statistically significant (Table 3) . After stratification for tumor characteristics and dissemination at diagnosis, odds ratios for breast cancer in heterozygotes versus noncarriers were 5.3 (95% CI, 1.5 to 19.0) in those patients with tumor size Յ 10 mm, 4.3 (95% CI, 1.2 to 15.3) and 3.0 (95% CI, 1.2 to 7.7) in those patients with grade 1 and unknown grades of malignancy in ductal carcinoma, 3.4 (95% CI, 1.6 to 7.5) in those patients with hormone-receptor-negative tumors, 5.3 (95% CI, 1.9 to 14.7) in those patients with tumor-positive lymph nodes without breakthrough of capsule, and 2.6 (95% CI, 1.2 to 5.8) in those patients with absent distant metastases (Table 4 ). In the other subgroups examined, the odds ratios were all higher than 1.0, but were not statistically significant.
Population-Attributable Risk of Breast Cancer
Based on a frequency of 0.5% for CHEK2*1100delC in the general population and a hazard ratio of 3.2 for breast cancer in female heterozygotes versus noncarriers, the population-attributable risk of breast cancer in women for CHEK2*1100delC was 1.1%.
Absolute Risk of Breast Cancer
The lowest absolute 10-year risk for breast cancer was 2% in female CHEK2*1100delC heterozygotes who were younger than 40 years old, with a body mass index lower than 25 kg/m 2 (Fig 2) . Absolute risk increased with increasing age, use of hormone replacement therapy, and a body mass index at or higher than 25 kg/m 2 . The highest absolute 10-year risk for breast cancer in CHEK2*1100delC heterozygotes was 24% in hormone replacement therapy users older than 60 years old with a body mass index at or higher than 25 kg/ m 2 .
DISCUSSION
CHEK2 is part of a phylogenetically conserved pathway that is activated in response to DNA damage. 1 This, together with the fact that a recent case-control study found an association between mutations in CHEK2 (IVS2ϩ1G3 A and 1100delC) and thyroid, breast, and prostate cancer, as well as between another variant (I157T) and breast, colon, kidney, prostate, and thyroid cancer, 22 support the hypothesis that CHEK2 may be a general cancer susceptibility gene. However, our Stratification by age, body mass index (BMI), alcohol consumption, parity, use of oral contraceptives (OCD), menopausal status, and use of hormonal replacement therapy (HRT). Numbers vary slightly due to incomplete information for some of the covariates used for stratification. ND, not determined. study in the Danish general population following 9,231 individuals for 34 years, during which 1,914 incident cancers developed, was not able to support this hypothesis.
The contribution of hereditary factors to the causation of breast cancer is 27% (95% CI, 4% to 41%).
23 BRCA1 and BRCA2 genes account for only 3% to 8% of all breast cancers in women. 24 In our prospective study, we found a carrier frequency of CHEK2*1100delC of 0.5% in the general population, similar to that observed in controls from Germany. 25 The 3.2-fold risk of breast cancer in CHEK2*1100delC heterozygotes found in the general population is similar to the 2.6-fold risk observed in our large case-control study, and to the 2.3-fold risk reported in a large multicenter case-control study by the CHEK2 Breast Cancer Consortium. 4 The 3.2-fold risk and a frequency of 0.5% results in a population-attributable risk of breast cancer in women of 1.1% for CHEK2*1100delC, or slightly less than the total of 3% to 8%, accounted for by all mutations in BRCA1 and BRCA2. 24 In populations with a CHEK2*1100delC heterozygosity frequency of 1.4%, like in Finland, 9 a 3.2-fold risk of breast cancer would imply a 3.0% population-attributable risk of breast cancer in women.
Our observation of positive odds ratios for breast cancer by CHEK2*1100delC heterozygosity in all strata, although some were not statistically significant, together with no evidence of statistical interaction between genotypes and context on breast cancer risk, support the interpretation that women heterozygous for CHEK2*1100delC have an increased risk of breast cancer regardless of age, body mass index, alcohol consumption, parity, use of oral contraceptives, menopausal status, and use of hormone replacement therapy. CHEK2*1100delC heterozygosity has been associated with an odds ratio of 1.7 to 2.1 in unselected Polish prostate cancer patients, increasing to 4.9 to 8.2 in Polish and Finnish heterozygotes with a positive family history of this disease. 10, 11, 22 Our findings of a hazard ratio of 2.3 (95% CI, 0.6 to 9.5) for prostate cancer by CHEK2*1100delC heterozygosity, although not statistically significant, is in line with these results.
Conflicting reports regarding the association between CHEK2*1100delC heterozygosity and colorectal cancer have been published previously; CHEK2*1100delC was first associated with colorectal cancer in Dutch families with hereditary breast and colorectal cancer, 7 whereas case-control studies in the Finland, Poland, and the United Kingdom reported no such association. 12,22,26 Although CHEK2*1100delC heterozygosity conferred a hazard ratio of 1.6 (95% CI, 0.4 to 6.5) for colorectal cancer in our study, this was not statistically significant.
To the best of our knowledge, we are the first to report an association between CHEK2*1100delC heterozygosity and brain and/or nerve tissue cancers. Previously, only one study examined the association between CHEK2*1100delC heterozygosity and leukemia; Collado et al examined 107 Spanish leukemia patients and found no CHEK2*1100delC heterozygotes 27 ; however, CHEK2*1100delC is nearly absent from the Spanish population, and this may explain their finding. 27, 28 Therefore, other studies are needed to confirm (or rebut) our findings of an association between CHEK2*1100delC and brain/ nerve tissue cancers and leukemia.
The association between CHEK2*1100delC and kidney cancer has been examined by Cybulski et al, 22 who observed an insignificant odds ratio of 2.7 (P ϭ .50). This is well below the hazard ratio of 9.8 that was observed in our prospective study; interestingly, however, that same article reported an odds ratio of 2.1 (P Ͻ .001) for kidney cancer by the CHEK2 I157T variant versus noncarriers. 22 There are some limitations to our study, First, the number of CHEK2*1100delC heterozygotes is limited. Second, only participants attending the 1991 to 1994 examination of the Copenhagen City Heart Study were genotyped. A selection bias might have occurred if death or morbidity prevented certain participants from attending the 1991 to 1994 examination. However, two observations make substantial selection bias against any genotype less likely. (1) In the general population, the frequency of noncarriers and heterozygotes do not increase or decrease as a function of age. (2) The distribution between genotypes was in Hardy-Weinberg equilibrium.
Third, misclassification of disease may have occurred. However, this is not very likely because we have 100% follow-up of participants, and because all hospital admissions and deaths are registered in the country. Furthermore, the Danish National Cancer Registry identifies 98% of all cancers in Denmark.
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A likely limitation of case-control studies is the selection of controls; however, we chose breast cancer-free female participants from the Danish general population as controls. Furthermore, cases and controls came from the same geographic area and were matched for age.
Our participants could be affected by selection bias. However, this is less likely to have occurred because, (1) participants were consecutively collected, and (2) blood samples were drawn within 30 days of breast cancer diagnosis in more than 80% of the cases, practically excluding that CHEK2*1100delC heterozygotes died selectively compared with noncarriers.
Women with CHEK2*1100delC may benefit from preventive examinations for breast cancer, preferably excluding ionizing radiation. 29 In contrast with screening all BRCA1 and BRCA2 genes, CHEK2*1100delC testing is a single genotyping test that costs less than US$10, which detects 100% of carriers. Cost-effectiveness analyses should evaluate whether CHEK2*1100delC genotyping followed by preventive examinations should be offered to only women with high risk of familial breast cancer or sporadic breast cancer, and/or who have other risk factors (Fig 2) , or if it should be offered to most women. 
